VEGFA and retinopathy of prematurity: The efficacious of anti-VEGF agents have been certified in several studies and the short-term safety was also described, while the peripheral vascular abnormalities of ROP treated with bevacizumab and ranibizumab had also been reported in recent years [14–17].